Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818508 | 0.89 | HTR6 (0.50) | HTR6ALDH1A1TSHRHSD17B10KMT2A | |
| SCHEMBL27404576 | 0.87 | HTR6 (0.58) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| SCHEMBL28198594 | 0.87 | HTR6 (0.52) | HTR6ALDH1A1CA12CA1CA2 | |
| (Phenylsulfonyl)Benzene SCHEMBL5537560 | 0.87 | HTR6 (0.93) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL1549229 | 0.87 | HTR6 (0.93) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL29775288 | 0.84 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL13735236 | 0.84 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL30255 | 0.84 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL29473549 | 0.84 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 | |
| (Phenylsulfonyl)Benzene SCHEMBL29450723 | 0.84 | HTR6 (1.00) | HTR6ALDH1A1SMN1; SMN2TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | claimed |
| CN-113831340-B | Can [ n ] dihydroacridine macrocycle and preparation method thereof | 中国科学院化学研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-108117548-B | Spirofluorene compound, application thereof, thermal activation delayed fluorescence material and organic electroluminescent device using spirofluorene compound | 北京鼎材科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113831340-A | Calix [ n ] dihydroacridine macrocycle and preparation method thereof | 中国科学院化学研究所 | 2021-12-24 | — | — | CN | claimed |
| CN-108117495-B | Spirofluorene ring compound, use thereof, and organic electroluminescent device using the same | 北京鼎材科技有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-107074824-B | Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer | 基因泰克公司 | 2021-01-08 | — | — | CN | claimed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | claimed |
| CN-108117495-A | Spiro fluorene cycle compound, its purposes and use its organic electroluminescence device | 北京鼎材科技有限公司 | 2018-06-05 | — | — | CN | claimed |
| CN-108117511-A | Spiro fluorene cycle compound, its purposes and use its organic electroluminescence device | 北京鼎材科技有限公司 | 2018-06-05 | — | — | CN | claimed |
| CN-108117548-A | Spiro fluorene cycle compound, its application and use its hot activation delayed fluorescence material and organic electroluminescence device | 北京鼎材科技有限公司 | 2018-06-05 | — | — | CN | claimed |
| EP-0237917-A2 | 1,1-Disubstituted cyclopropane derivatives, processes for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-23 | — | — | EP | claimed |
| EP-0236700-A1 | Alpha,beta-substituted acroleins, process for their production and their use | BASF Aktiengesellschaft (DE) | 1987-09-16 | — | — | EP | claimed |
| EP-0236913-A2 | Aryl-azolylmethyl-benzocyclo-alkene derivatives, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-16 | — | — | EP | claimed |
| CN-85109721-A | Preparation has the ectoparasite of the no disease homoiothermic animal of control and the method for endoparasite compositions | — | 1987-07-15 | — | — | CN | claimed |
| EP-0211004-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | RHONE-POULENC NEDERLAND B.V. (NL) | 1987-02-25 | — | — | EP | claimed |
| EP-0094038-B1 | 3-AMINO-6-ARYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES, THEIR PREPARATION AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-07 | — | — | EP | claimed |
| WO-1986003941-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | UNION CARBIDE CORPORATION (US) | 1986-07-17 | — | — | WO | claimed |
| EP-0121490-A1 | Substituted 6-aryl-1,2,4-triazolo[4,3-b]pyridazines, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-10-10 | — | — | EP | claimed |
| EP-0094038-A1 | 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)pyridazines, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-16 | — | — | EP | claimed |
| US-4048153-A | Azo dyes having an optionally substituted 1-azo-3-nitro-4-arylaminophenyl nucleus | SANDOZ LTD. (CH) | 1977-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | HTR6 3724/4885ALDH1A1 2604/4885SMN1; SMN2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.